COLLAGEN DIAGNOSTIC LABORATORY

UW LABORATORY FOR PRECISION DIAGNOSTICS

Peter H. Byers, MD, University of Washington, Lab H-561 Health Sciences, 1959 NE Pacific St, Seattle, WA 98195 Main Phone (206) 543-0459; Genetic Counselors (206) 543-5464; Fax (206) 616-1899; www.uwcpdx.org

LABORATORY TEST REQUISITION FORM

| PATIENT INFORMATION | REPORTING RESULTS | | | | | |
|--|---|--|--|--|--|--|
| NAME: | REFERRING PHYSICIAN (REQUIRED): | | | | | |
| DOB: | NAME: | | | | | |
| SEX: MALE FEMALE | NPI #: | | | | | |
| YOUR PATIENT ID#: | PHYSICIAN SPECIALTY: | | | | | |
| ADDRESS: | GENETIC COUNSELOR: | | | | | |
| | INSTITUTION: | | | | | |
| | ADDRESS: | | | | | |
| PHONE: | CITY: STATE: ZIP: | | | | | |
| C 1 1 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 | COUNTRY: | | | | | |
| SAMPLE TYPE: | PHONE: | | | | | |
| | FAX: | | | | | |
| ☐ Blood (PREFERRED) 5-7cc, purple top EDTA | EMAIL: | | | | | |
| DNA (minimum 1μg; must be extracted in | | | | | | |
| CLIA accredited or other suitable lab) | REFERRING LAB: | | | | | |
| ☐ Saliva | SEND OUT COORDINATOR: | | | | | |
| Amniocytes (2 T25-flasks, cultured) | ADDRESS: | | | | | |
| CVS Cells (2 T-25 flasks, cultured) | CITY: STATE: ZIP: | | | | | |
| Other: | COUNTRY: | | | | | |
| | PHONE: | | | | | |
| COLLECTION DATE: | FAX: | | | | | |
| data registries and/or for publication. Individual | ied data from tested individuals may be submitted to clinical genetic ls may refuse to allow CDL to use their information and specimen by ng policy and research approach is available at www.uwcdl.org | | | | | |
| CLINICAL INFORMATION – PLEASE ATTACH CLINIC NOTE | | | | | | |
| SUSPECTED DIAGNOSIS: | | | | | | |
| ☐ Osteogenesis Imperfecta ☐ Ehlers-Danlos Synd | rome Marfan Syndrome Loeys-Dietz Syndrome | | | | | |
| ☐ Familial Aneurysm Syndrome ☐ Other: | | | | | | |
| CLINICAL DESCRIPTION – PLEASE ATTACH CLINIC ☐ Blue sclerae ☐ Hearing Loss ☐ High arched | | | | | | |
| ☐ Translucent skin ☐ Easy bruising ☐ Atrophic sca | | | | | | |
| ☐ Bone deformity ☐ Short Stature ☐ Joint hypern | | | | | | |
| Fractures (age and location): | | | | | | |
| ☐ Vascular Event: dissection, aneurysm, rupture (age and | location): | | | | | |
| unout only rup time (age and | / - | | | | | |
| Other findings/history: | | | | | | |
| Positive family history (please include pedigree) | | | | | | |
| , | | | | | | |

TEST REQUESTED (See website for current costs and CPT codes)

| | Mutation/Variant Testing (Please provide positive control and copy of report if testing done at another laboratory) | | | | | | |
|----------|--|--|--|--|--|--|--|
| Name o | of Relative (Proband): CDL#: Relationship to Proband: | | | | | | |
| Gene: | Mutation/Variant to be tested: | | | | | | |
| Panels a | nd single gene tests include both sequencing and deletion/duplication analysis by next-generation sequencing | | | | | | |
| Osteog | genesis Imperfecta (OI) and genetic bone disorders | | | | | | |
| | Autosomal Dominant OI Panel (COL1A1, COL1A2, IFITM5) | | | | | | |
| | OI and Genetic Bone Disorders Panel (ALPL, B3GAT3, B4GALT7, BMP1, CCDC134, COL1A1, COL1A2, CREB3L1, CRTAP, FAM46A/TENT5A, FGFR3, FKBP10, GORAB, IFITM5, KDELR2, LRP5, MBTPS2, MESD, NBAS, P3H1, P4HB, PLOD2, PLOD3, PLS3, PPIB, RUNX2, SEC24D, SERPINF1, SERPINH1, SP7, SPARC, TAPT1, TMEM38B, TNFRSF11B, WNT1, XYLT2) | | | | | | |
| In | dividual Genes: | | | | | | |
| | COL1A1 and COL1A2 | | | | | | |
| | IFITM5 | | | | | | |
| | Caffey Disease (COL1A1 c.3040C>T), Sanger sequencing | | | | | | |
| | Hypophosphatasia (ALPL) | | | | | | |
| | X-Linked Osteoporosis (PLS3) | | | | | | |
| Osteo | petrosis Panel | | | | | | |
| | (AMER1, CA2, CLCN7, CTSK, FAM20C, FERMT3, LEMD3, LRP5, OSTM1, PLEKHM1, SNX10, TCIRG1, TNFRSF11A, TNFSF11) | | | | | | |
| Ehlers | -Danlos Syndromes (EDS) | | | | | | |
| | Comprehensive EDS Panel (ADAMTS2, AEBP1, ATP7A, C1R, C1S, CHST14, COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, DSE, FKBP14, FLNA, PLOD1, SLC39A13) | | | | | | |
| | Classical and Vascular EDS Panel (COL5A1, COL5A2, COL3A1) | | | | | | |
| | Classical EDS (COL5A1 and COL5A2) | | | | | | |
| | Vascular EDS (COL3A1) | | | | | | |
| | Arthrochalasia EDS (Exon 6 COL1A1/COL1A2), Sanger sequencing | | | | | | |
| | Dermatosparaxis EDS (ADAMTS2) | | | | | | |
| | Kyphoscoliotic EDS (PLOD1 and FKBP14) | | | | | | |
| | Periodontal EDS (C1S and C1R) | | | | | | |
| Comp | olex EDS-like Disorders | | | | | | |
| | (B3GALT6, B4GALT7, B3GAT3, CHST14, CHST3, XYLT1) | | | | | | |
| Vascu | ılar Genetic Disorders | | | | | | |
| | Arterial Aneurysm Panel (ACTA2, BGN, CBS, COL1A1, COL3A1, FBN1, FBN2, FOXE3, LOX, MAT2A, MFAP5, MYH11, MYLK, NOTCH1, PLOD3, PRKG1, SKI, SLC2A10, SMAD2, SMAD3, SMAD4, SMAD6, TGFB2, TGFB3, TGFBR1, TGFBR2) | | | | | | |
| | Marfan Syndrome and Loeys-Dietz Syndrome Panel (FBN1, SMAD2, SMAD3, SMAD4, TGFB2, TGFB3, TGFBR1, TGFBR2) | | | | | | |
| | Marfan syndrome (FBN1) | | | | | | |
| | COL4A1 and COL4A2 Related Disorders (COL4A1 and COL4A2) | | | | | | |
| Cutis | Laxa Panel | | | | | | |
| | (ALDH18A1, ATP6V0A2, ATP6V1A, ATP6V1E1, ATP7A, EFEMP2, ELN, FBLN5, GORAB, LTBP4, PYCR1, RIN2, SLC2A10) | | | | | | |
| Ector | pia Lentis Panel | | | | | | |
| | (ADAMTS10, ADAMTS17, ADAMTSL4, CBS, FBN1) | | | | | | |
| Alpo | ort Syndrome | | | | | | |
| | Alport Syndrome Panel (COL4A3, COL4A4, COL4A5) | | | | | | |
| | X-Linked Alport Syndrome (COL4A5) | | | | | | |
| Stick | kler Syndrome | | | | | | |
| | Stickler Panel (COL2A1, COL9A1, COL9A2, COL9A3, COL11A1, COL11A2) | | | | | | |
| Othe | er Tests | | | | | | |
| | Maternal Cell Contamination Studies (fragment analysis) | | | | | | |
| | Targeted pre-mRNA Splicing Analysis (cultured fibroblasts required) | | | | | | |

COLLAGEN DIAGNOSTIC LABORATORY

BILLING INFORMATION

Requested laboratory testing will be initiated only AFTER accurate billing information is provided.

Canadian samples: Providers must acquire approval of all tests, including reflex testing, before submitting samples.

| BILL INSTITUTION: | INSTITUTIO | NAL BILLIN | <u>G</u> | | | |
|--|-------------------|-----------------|-------------------------|----------------------------|--------------------|--|
| Institution Name: | | | | | | |
| Tax ID Number: | PC | D#: | | | | |
| City: | State: | ZIP: | | | | |
| Phone: | Fax: | | | | | |
| Send Result Report: | | | | | | |
| BILL PATIENT: SELF-P. | AY or INTERN | ATIONAL S | AMPLES | | | |
| Check (payable to UW Physicians) or Money Order Amount (USD): | | | | | | |
| Credit Card: Please co | ntact CDL billir | ıg at (206) 685 | -5007 to provide credit | card information over a se | ecure line. | |
| Electronic Funds Transfer (EFT) (See website for details) EFT Amount: USD | | | | | | |
| BILL INSURANCE: PATIENT INSURANCE *Patient needs to sign billing consent below* Preauthorization is required for all insurance billing over \$600.00 (note testing is not started until pre-authorization complete) Do insurance preauthorization PROCEED if approved; include PreAuth Form. Clinic notes are required. | | | | | | |
| Preauthorization alre | ady obtained; P | reAuth appro | val# | At | ttach copy of P.A. | |
| Please attach a copy of c Name on Policy: | ard for all insi | ırance billing | , | | | |
| • | Self Parent | • | Other (please specify | ⁷): | | |
| Cardholder DOB: | Dates of Co | verage: | | | | |
| Patient Policy ID#: | | | | | | |
| Group Name: | | Group #: | | | | |
| Insurance Co. Name: | | | | | | |
| *Patient Insurance Billing Consent: I authorize the CDL to release to my designated insurance carrier, health plan, or third party administrator the information on this form and any other information provided by my health care provider necessary for reimbursement. I assign and authorize insurance payments to the CDL. I understand my insurance carrier may not approve and reimburse my medical genetic services in full due to usual and customary rate limits, benefit exclusions, coverage limits, lack of authorization, medical necessity, or otherwise. I understand I am responsible for fees not paid in full, co-payments, and policy deductibles except where my liability is limited by contract or State or Federal law. A duplicate or faxed copy of this authorization is considered the same as the original document. | | | | | | |
| Patient Signature: | | | Date: | | | |
| BILL MEDICARE: Medicare does not pre-authorize under any circumstances. | | | | | | |
| A completed Advance Beneficiary Notice (ABN) is required for Medicare patients (see website). | | | | | | |

SHIP SAMPLE OVERNIGHT TO:

Peter H. Byers, MD
UW Laboratory for Precision Diagnostics
H-561, Health Science Bldg.
1959 NE Pacific Street
Seattle, WA 98195